Skip to main content
SpringerLink
Log in

Immunotherapy

  • Chapter
  • First Online:
Atlas of Rheumatoid Arthritis

  • 2826 Accesses

Abstract

The mainstay of treatment for rheumatoid arthritis (RA)—use of disease modifying antirheumatic drugs (DMARDs)—affects a range of cellular targets in the immune system. Conventional synthetic or nonbiological DMARDs (nbDMARDs), so-called for their ability to modulate the impact of the disease on joint damage, have historically been discovered through experimental use. Their mechanisms of action in the immune system, however, have not yet been fully elucidated. Increased understanding of the pathogenesis of RA has led to the development of biological DMARDs (bDMARD), with specific targets including cytokines, immune cells, and immune pathways.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Louie GH, Ward MM. Changes in the rates of joint surgery among patients with rheumatoid arthritis in California, 1983–2007. Ann Rheum Dis. 2010;69:868-871.

    Google Scholar 

  2. Sodergren A, Stegmayr B, Lundberg V, Ohman ML, Wallberg-Jonsson S. Increased incidence of and impaired prognosis after acute myocardial infarction among patients with seropositive rheumatoid arthritis. Ann Rheum Dis. 2007;66:263-266.

    Google Scholar 

  3. Westlake SL, Colebatch AN, Baird J, et al. Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology. 2011;50:518-531.

    Google Scholar 

  4. Smolen JS, Aletaha D, Bijlsma JW, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-637.

    Google Scholar 

  5. Singh JA, Furst DE, Bharat A, et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64:625-639.

    Google Scholar 

  6. Furst DE, Keystone EC, Braun J, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis. 2012;71:i2-i45.

    Google Scholar 

  7. Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 2007;56:1125-1133.

    Google Scholar 

  8. Askling J, Fored CM, Brandt L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis. 2007;66:1339-1344.

    Google Scholar 

  9. Wolfe F, Caplan L, Michaud K, Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. Arthritis Rheum. 2006;54:628-634.

    Google Scholar 

  10. Dixon WG, Symmons DP, Lunt M, Watson KD, Hyrich KL, Silman AJ. Serious infection following antitumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. Arthritis Rheum. 2007;56:2896-2904.

    Google Scholar 

  11. Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011;50:124-131.

    Google Scholar 

  12. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999;340:253-259

    Google Scholar 

  13. Keystone E, Van Der Heijde D, Mason D, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2008;58:3319-3329.

    Google Scholar 

  14. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet. 1999;354:1932-1939.

    Google Scholar 

  15. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum. 2003;48:35-45.

    Google Scholar 

  16. Keystone E, Genovese MC, Klareskog L, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis. 2010;69:1129-1135.

    Google Scholar 

  17. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54:1390-1400.

    Google Scholar 

  18. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis. Ann Intern Med. 2006;144:865-876.

    Google Scholar 

  19. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54:2817-2829.

    Google Scholar 

  20. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necro sis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009;68:1136-1145.

    Google Scholar 

  21. Johnston A, Gudjonsson JE, Sigmundsdottir H, Runar Ludviksson B, Valdimarsson H. The antiinflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol. 2005;114:154-163.

    Google Scholar 

  22. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69:964-975.

    Google Scholar 

  23. Luqmani R, Hennell S, Estrach C, et al. British Society for Rheumatology and British Health Professionals in Rheumatology Guideline for the Management of Rheumatoid Arthritis (the first two years). Rheumatology. 2006;45:1167-1169.

    Google Scholar 

  24. Gaujoux-Viala C, Smolen JS, Landewe R, et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2010;69:1004-1009.

    Google Scholar 

  25. Choy EHS, Smith C, Dore CJ, Scott DL. A meta-analysis of the efficacy and toxicity of combining diseasemodifying antirheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology. 2005;44:1414-1421.

    Google Scholar 

  26. Nam JL, Winthrop KL, Van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis. 2010;69:976-986.

    Google Scholar 

  27. Smedegard G, Bjork J. Sulphasalazine: mechanism of action in rheumatoid arthritis. Br J Rheumatol. 1995;34(suppl 2):7-15.

    Google Scholar 

  28. Rahav G, Zylber-Katz E, Rachmilewitz D, Levy M. Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases. Isr J Med Sci. 1990;26:31-34.

    Google Scholar 

  29. Katz SJ, Russell AS. Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action. Curr Opin Rheumatol. 2011;23:278-281.

    Google Scholar 

  30. Fox RI, Herrmann ML, Frangou CG, et al. Mechanism of action for leflunomide in rheumatoid arthritis Clin Immunol. 1999;93:198-208.

    Google Scholar 

  31. Bos WH, Wolbink GJ, Boers M, et al. Arthritis development in patients with arthralgia is strongly associated with anti-citrullinated protein antibody status: a prospective cohort study. Ann Rheum Dis. 2010;69:490-494.

    Google Scholar 

  32. Nielen MMJ, Van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: A study of serial measurements in blood donors. Arthritis Rheum. 2004;50:380-386.

    Google Scholar 

  33. Cuthbert R, Parmar R, Nam J, et al. T-cell subsets dys-regulation and cytokines are predictive of RA pathogenesis in an ACPA-positive background. Arthritis Rheum. 62 (suppl 10):S455.

    Google Scholar 

  34. Confavreux CB, Chapurlat RD. Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis. Osteoporos Int. 2011;22:1023-1036.

    Google Scholar 

  35. Brennan F, Jackson A, Chantry D, Maini R, Feldmann M. Inhibitory effect of TNF-α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet. 1989;334:244-247.

    Google Scholar 

  36. Buch MH, Bingham SJ, Bryer D, Emery P. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Rheumatology (Oxford). 2007;46:1153-1156.

    Google Scholar 

  37. Mease, P. Atlas of Psoriatic Arthritis. London, UK: Current Medicine Group; 2005.

    Google Scholar 

  38. Wolf D, Mahadevan U. Certolizumab Pegol use in pregnancy: low levels detected in cord blood (abstract). Arthritis Rheum. 2010;62(suppl10):299.

    Google Scholar 

  39. Porter C, Kopotsha T, Smith B, Nesbitt A, Urbaniak S, Armstrong-Fisher S. No significant transfer of certolizumab pegol compared with IgG in the perfused human placenta in vitro (abstract). Ann Rheum Dis. 2010;69 (suppl 3):210.

    Google Scholar 

  40. Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti-tumor necrosis factor α agents. Inflamm Bowel Dis. 2007;13:1323-1332.

    Google Scholar 

  41. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther. 2008;117:244-279.

    Google Scholar 

  42. Taylor PC. Pharmacology of TNF blockade in rheumatoid arthritis and other chronic inflammatory diseases. Current Opin Pharmacol. 2010;10:308-315.

    Google Scholar 

  43. Taylor RP, Lindorfer MA. Drug Insight: the mechanism of action of rituximab in autoimmune disease – the immune complex decoy hypothesis. Nat Clin Pract Rheumatol. 2007;3:86-95.

    Google Scholar 

  44. Dass S, Rawstron AC, Vital EM, Henshaw K, Mcgonagle D, Emery P. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum. 2008;58:2993-2999.

    Google Scholar 

  45. Ruderman EM, Pope RM. Drug insight: abatacept for the treatment of rheumatoid arthritis. Nat Clin Pract Rheumatol. 2006;2:654-660.

    Google Scholar 

  46. Mihara M, Tan I, Chuzhin Y, et al. CTLA4Ig inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus. J Clin Invest. 2000;106:91-101.

    Google Scholar 

  47. Kishimoto T. Interleukin-6: discovery of a pleiotropic cytokine. Arthritis Res Ther. 2006; 8(suppl. 2):S2. 48. Muraguchi A, Hirano T, Tang B, et al. The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells. J Exp Med. 1988;167:332-344. 49. Lotz M, Jirik F, Kabouridis P, et al. B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes. J Exp Med. 1988;167:1253-1258.

    Google Scholar 

  48. Smolen JS, Han C, Bala M, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: A detailed subanalysis of data from the anti–tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum. 2005;52:1020-1030.

    Google Scholar 

  49. Dougados M, Huizinga T, Sheeran T, et al. Tocilizumab (TCZ) plus methotrexate (MTX) does not have superior clinical efficacy to TCZ alone in RA patients with inadequate response to MTX: 24-week results of the ACT-RAY study (abstract). Ann Rheum Dis. 2011;70:73.

    Google Scholar 

  50. Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER stud.y): a multicentre, randomised, doubleblind, placebo-controlled, phase III trial. Lancet. 2009;374:210-221.

    Google Scholar 

  51. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54:2793-2806.

    Google Scholar 

  52. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67:1516-1523.

    Google Scholar 

  53. Genovese MC, Becker J-C, Schiff M, et al. Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition. N Eng J Med. 2005;353:1114-1123.

    Google Scholar 

  54. Gabay C, Emery P, Van Vollenhoven R, et al. Tocilizumab (TCZ) monotherapy is superior to adalimumab (ADA) monotherapy in reducing disease activity in patients with rheumatoid arthritis (RA): 24-week data from the phase 4 ADACTA trial. Ann Rheum Dis. 2012;71(suppl 3):152.

    Google Scholar 

  55. Schiff M, Fleischmann R, Weinblatt M, et al. Abatacept versus adalimumab on background methotrexate in RA: one year results from the AMPLE study. Ann Rheum Dis. 2012;71(suppl 3):60.

    Google Scholar 

  56. St Clair EW, Van Der Heijde D, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. 2004;50:3432-3443.

    Google Scholar 

  57. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37. 1094-1108.

    Google Scholar 

  58. Bejarano V, Conaghan PG, Quinn MA, Saleem B, Emery P. Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis. Rheumatology. 2010;49:1971-1974.

    Google Scholar 

  59. Quinn MA, Conaghan PG, O’Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2005;52:27-35.

    Google Scholar 

  60. Saleem B, Keen H, Goeb V, et al. Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis. 2010;69:1636-1642.

    Google Scholar 

  61. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263-269.

    Google Scholar 

  62. Verstappen SMM, Jacobs JWG, Van Der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis. 2007;66:1443-1449.

    Google Scholar 

  63. . Van Vollenhoven RF, Ernestam S, Geborek P, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet. 2009;374:459-466.

    Google Scholar 

  64. Goekoop-Ruiterman YPM, De Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis. Ann Intern Med. 2007;146:406-415.

    Google Scholar 

  65. Moreland LW, O’Dell JR, Paulus HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early, aggressive rheumatoid arthritis. Arthritis Rheum. 2012; 64:2824-2835.

    Google Scholar 

  66. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis Lancet. 1997;350:309-318.

    Google Scholar 

  67. Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet. 1999;353:1568-1573.

    Google Scholar 

  68. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2008;59:762-784.

    Google Scholar 

  69. Dawson TM, Starkebaum G, Wood BL, Willkens RF, Gown AM. Epstein-Barr virus, methotrexate, and lymphoma in patients with rheumatoid arthritis and primary Sjogren’s syndrome: case series. J Rheumatol. 2001;28:47-53.

    Google Scholar 

  70. European Medicines Agency (EMA). EMA Public Statement on Leflunomide (Arava) - severe and serious hepatic reactions. EMA website. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/ news/2010/08/news_detail_001088.jsp&mid=WC0b01ac058004d5c1. Updated October 25, 1999. Accessed March 6, 2015.

  71. Marmor MF, Kellner U, Lai TYY, Lyons JS, Mieler WF. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118:415-422.

    Google Scholar 

  72. Smitten AL, Simon TA, Hochberg MC, Suissa S. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10:R45.

    Google Scholar 

  73. Watson KD, Dixon WG, Hyrich KL, Lunt M, Symmons DP, Silman AJ. Influence of anti-TNF therapy and previous malignancy on cancer incidence in patients with rheumatoid arthritis (RA): results from the BSR biologics register (abstract). Ann Rheum Dis. 2006;65:512.

    Google Scholar 

  74. Strangfeld A, Hierse F, Rau R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther. 2010;12:R5.

    Google Scholar 

  75. Dixon WG, Symmons DPM, Lunt M, Watson KD, Hyrich KL, Silman AJ. Serious infection following anti-tumor necrosis factor α therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studies. Arthritis Rheum. 2007;56:2896-2904.

    Google Scholar 

  76. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis. 2010;69:522-528.

    Google Scholar 

  77. Mariette X, Gottenberg J-E, Ravaud P, Combe B. Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries. Rheumatology. 2011;50:222-229.

    Google Scholar 

  78. Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:909-920.

    Google Scholar 

  79. Schiff MH, Kremer JM, Jahreis A, Vernon E, Isaacs JD, Van Vollenhoven RF. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther. 2011;13:R141.

    Google Scholar 

  80. Lang VR, Englbrecht M, Rech J, et al. Risk of infections in rheumatoid arthritis patients treated with tocilizumab. Rheumatology. 2012;51:852-857.

    Google Scholar 

  81. Mariette X, Matucci-Cerinic M, Pavelka K, et al. Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis. 2011;70:1895-1904.

    Google Scholar 

  82. Dass S, Vital EM, Emery P. Development of psoriasis after B cell depletion with rituximab. Arthritis Rheum. 2007;56:2715-2718.

    Google Scholar 

  83. Dixon WG, Hyrich KL, Watson KD, et al. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2010;69:1086-1091. 70:1542-1549.

    Google Scholar 

  84. Hadjinicolaou AV, Nisar MK, Bhagat S, Parfrey H, Chilvers ER, Ostor AJK. Non-infectious pulmonary complications of newer biological agents for rheumatic diseases – a systematic literature review. Rheumatology. 2011;50: 2297-2305.

    Google Scholar 

  85. Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 2010;62: 2625-2632.

    Google Scholar 

  86. Hawker K, O’Connor P, Freedman MS et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66: 460-471.

    Google Scholar 

  87. Hwang WYK, Foote J. Immunogenicity of engineered antibodies. Methods. 2005;36:3-10.

    Google Scholar 

  88. Genovese MC, Mociran E, Biagini M, Bojin S, Sloan-Lancaster J. Phase 2 study of safety and efficacy of a novel anti-BAFF monoclonal antibody, in patients with RA treated with methotrexate [abstract]. Arthritis Rheum. 2009;60 (suppl 10):1923.

    Google Scholar 

  89. Genovese MC, Van Den Bosch F, Roberson SA, et al. LY2439821, a humanized anti–interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 2010;62:929-939.

    Google Scholar 

  90. Genovese MC, Durez P, Richards HB, et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis. 2013;72:863-869.

    Google Scholar 

  91. Šenolt L, Gothberg M, Valencia X, Dokoupilova E. Efficacy and safety of NNC0109-0012 (anti-Il-20 mAb) in patients with rheumatoid arthritis: results from a phase 2a trial [abstract]. Ann Rheum Dis. 2012;71:152.

    Google Scholar 

  92. Burmester GR, Feist E, Sleeman MA, Wang B, White B, Magrini F. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, Phase I, first-in-human study. Ann Rheum Dis. 2011;70:1542-1549.

    Google Scholar 

  93. Rudnev A, Ragavan S, Trollmo C, et al. Selective activation of naturally occurring regulatory T cells by the monoclonal antibody BT-061. Markers of clinical activity and early phase II results in patients with rheumatoid arthritis (abstract). Arthritis Rheum. 2010;62:1125.

    Google Scholar 

  94. Van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis. N Eng J Med. 2012;367:508-519.

    Google Scholar 

  95. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, et al. Treatment of rheumatoid arthritis with a syk kinase inhibitor: A twelve-week, randomized, placebo-controlled trial. Arthritis Rheum. 2008;58:3309-3318.

    Google Scholar 

  96. Tebib J, Mariette X, Bourgeois P, et al. Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, Phase 2a study. Arthritis Res Ther. 2009;11:R95.

    Google Scholar 

  97. Genovese MC, Kavanaugh A, Weinblatt ME et al. An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum. 2011;63:337-345.

    Google Scholar 

  98. Mccann F, Palfreeman A, Andrews M, et al. Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther. 2010;12:R107.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

    Sarah C. Horton & Maya H. Buch

  2. NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK

    Sarah C. Horton & Maya H. Buch

Authors
  1. Sarah C. Horton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maya H. Buch
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Leeds Musculoskeletal Biomedical Research Unit, Leeds, West Yorkshire, United Kingdom

    Paul Emery

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer Healthcare

About this chapter

Cite this chapter

Horton, S.C., Buch, M.H. (2015). Immunotherapy. In: Emery, P. (eds) Atlas of Rheumatoid Arthritis. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-907673-91-7_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-907673-91-7_10

  • Published:

  • Publisher Name: Springer Healthcare, Tarporley

  • Print ISBN: 978-1-907673-90-0

  • Online ISBN: 978-1-907673-91-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation